TSI Group finalizes Yessamin, Ltd. deal and expands China base

August 16, 2012

Missoula, MT – 


TSI Group, the Hong Kong registered global researcher, developer and manufacturer of ingredients and finished products, has finalized the purchase of Yessamin Health Company, Ltd., a Norwegian invested contract manufacturing facility in Nantong, Jiangsu Province, China. This strategic acquisition has significantly elevated manufacturing and supply chain strengths and capabilities for the TSI Group according to Larry Kolb, TSI Group managing director of the innovation products division in Missoula, MT.

Yessamin was operating as a contract manufacturer producing and packaging tablets, hard two-piece gelatin, vegetarian capsules and softgels for dietary supplements, including technical support within QA/QC and production planning, primarily serving the Scandinavian countries of Norway, Sweden and Denmark, as well as China. With Yessamin facilities being BRC, NSF and GMP certified, TSI Group saw this acquisition as an excellent way to expand its capabilities in China.

Coupled with five existing manufacturing facilities and Q/C infrastructure platform in China, TSI now has added Yessamin as the newest finished dose manufacturer under their umbrella to expand its capabilities in manufacturing and supply chain management.

"We have invested heavily in the development of innovative products and established strategic collaborations that will develop market changing products for our global customers," said Kolb. "We strategically positioned ourselves to serve customers looking for a reliable Asian manufacturing partner to produce products that support brands entering the emerging Chinese market."

Kolb adds that the future of dietary supplement manufacturing in China is very bright. "The country as a whole is already the largest supplier of the raw materials in the supplement industry and the quality standard of Chinese manufacturers has improved significantly in recent years," Kolb said.

TSI Group has continued to evolve over the past decade to excel in superior manufacturing processes and assurances to become one of the leading developers and producers of nutraceutical products sold in over 30 countries. In addition to its China and U.S. base, TSI Group also maintains offices in Australia and Japan.

« Back

Back to Top
Contact Us
TSI Group Ltd.
These statements have not been evaluated by the Food and Drug Administration. Products described are not intended to diagnose, treat, cure or prevent any disease.
© 2020 TSI Group Ltd. All rights reserved.